SCHEMBL4516374

SCHEMBL4516374

Cc1ccc2c(-c3cccc(F)c3)ccnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.48
GRM4 Q14833 2/20 0.45
TLR8 Q9NR97 3/20 0.45
HTR1A P08908 2/20 0.43
ADRA1D P25100 2/20 0.43
ADRA1A P35348 2/20 0.43
ADRA1B P35368 2/20 0.43
PIM1 P11309 2/20 0.43
CDC7 O00311 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PRKACA P17612 1/20 0.43
CDK2 P24941 1/20 0.43
GSK3B P49841 1/20 0.43
HIPK2 Q9H2X6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43
AAK1 Q2M2I8 1/20 0.42
MTOR P42345 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756601 0.83 GRM2 (0.53) GRM4TLR8HTR1AADRA1DADRA1A
SCHEMBL757488 0.83 PIK3CA (0.50) GRM4TLR8HTR1AADRA1DADRA1A
SCHEMBL4507913 0.82 TLR8 (0.56) TOP2AGRM4TLR8PIM1CDC7
SCHEMBL28659657 0.81 GRM4 (0.61) TOP2AGRM4PIM1CDC7ROCK2
SCHEMBL15452489 0.78 CYP2A6 (0.54) TLR8HTR1AADRA1DADRA1AADRA1B
SCHEMBL21982345 0.75 ACVR1 (0.52) GRM4MAPTNPSR1NPC1RAB9A
SCHEMBL29287969 0.75 PIK3CA (0.49) HTR1AADRA1DADRA1AADRA1BMAP4K4
SCHEMBL16247654 0.75 MAP4K4 (0.57) GRM4PIM1CDC7ROCK2MAP4K4
SCHEMBL4523612 0.74 GRM2 (0.46) MAPTSMN1; SMN2TP53THRBALOX15
SCHEMBL16549213 0.73 MAP4K4 (0.50) TOP2AGRM4PIM1CDC7ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054483-A1 Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis MERCK FROSST CANADA LTD. (CA) 2009-02-26 US disclosed
US-20090054483-A1 Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis MERCK FROSST CANADA LTD. (CA) 2009-02-26 US disclosed
US-20090054483-A1 Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis MERCK FROSST CANADA LTD. (CA) 2009-02-26 US disclosed
EP-1934205-A1 SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS Merck Frosst Canada Ltd. (CA) 2008-06-25 EP disclosed
WO-2007038865-A1 SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA LTD. (CA) 2007-04-12 WO disclosed
WO-2007038865-A1 SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA LTD. (CA) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054483-A1 Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis LTC4S, LTA4H, LTB4R2 TOP2A 2081/4885GRM4 4282/4885TLR8 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.